Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentina Tuninetti

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Tumori|January 7, 2023
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM societyAndrea Milani, Valentina Tuninetti, Sandro Pignata, et al.
BMJ Oncology|January 31, 2025
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research studyLaura Marandino, Federica Trastu, Eleonora Ghisoni, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research studyAlessandro Rossi, Giacomo Aimar, Marco Audisio, et al.
Cancers|January 11, 2024
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control StudyMargherita Turinetto, Andrea Ricotti, Claudia Marchetti, et al.
Gynecologic Oncology|March 25, 2023
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trialLucia Musacchio, Margherita Turinetto, Laura Arenare, et al.
Frontiers in Oncology|February 6, 2024
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitorsFrancesca Arezzo, Gaia Giannone, Daniele Castaldo, et al.
Frontiers in Oncology|June 13, 2022
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO SurveyGaia Giannone, Daniele Castaldo, Valentina Tuninetti, et al.
Frontiers in Oncology|October 2, 2023
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitorsFrancesca Arezzo, Gaia Giannone, Daniele Castaldo, et al.
Journal of Cachexia, Sarcopenia and Muscle|October 13, 2025
Peripheral Thyroid Hormones, Inflammatory and Skeletal Muscle Indexes in Advanced Cervical Cancer Treated With CemiplimabValentina Tuninetti, Elisa Virano, Amedeo Calvo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2024
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 studyValentina Tuninetti, Elisa Virano, Vanda Salutari, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Tumori|January 7, 2023
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM societyAndrea Milani, Valentina Tuninetti, Sandro Pignata, et al.
BMJ Oncology|January 31, 2025
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research studyLaura Marandino, Federica Trastu, Eleonora Ghisoni, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research studyAlessandro Rossi, Giacomo Aimar, Marco Audisio, et al.
Cancers|January 11, 2024
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control StudyMargherita Turinetto, Andrea Ricotti, Claudia Marchetti, et al.
Gynecologic Oncology|March 25, 2023
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trialLucia Musacchio, Margherita Turinetto, Laura Arenare, et al.
Frontiers in Oncology|February 6, 2024
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitorsFrancesca Arezzo, Gaia Giannone, Daniele Castaldo, et al.
Frontiers in Oncology|June 13, 2022
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO SurveyGaia Giannone, Daniele Castaldo, Valentina Tuninetti, et al.
Frontiers in Oncology|October 2, 2023
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitorsFrancesca Arezzo, Gaia Giannone, Daniele Castaldo, et al.
Journal of Cachexia, Sarcopenia and Muscle|October 13, 2025
Peripheral Thyroid Hormones, Inflammatory and Skeletal Muscle Indexes in Advanced Cervical Cancer Treated With CemiplimabValentina Tuninetti, Elisa Virano, Amedeo Calvo, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2024
Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 studyValentina Tuninetti, Elisa Virano, Vanda Salutari, et al.
Pageof 4